NCT03344640View on ClinicalTrials.gov

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

August 2, 2019

Study Completion Date

October 17, 2019

Conditions
Tendinopathy
Interventions
DRUG

secukinumab

AIN457 300 mg subcutaneously for 12 weeks

OTHER

Placebo

Placebo to match AIN457 subcutaneously for 12 weeks

Trial Locations (12)

10117

Novartis Investigative Site, Berlin

22415

Novartis Investigative Site, Hamburg

33014

Novartis Investigative Site, Miami Lakes

33603

Novartis Investigative Site, Tampa

33765

Novartis Investigative Site, Clearwater

66250

Novartis Investigative Site, Brno

85053

Novartis Investigative Site, Phoenix

91942

Novartis Investigative Site, La Mesa

280 02

Novartis Investigative Site, Kolín

Unknown

Novartis Investigative Site, Prague

2333 CL

Novartis Investigative Site, Leiden

G51 4TF

Novartis Investigative Site, Glasgow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY